PURPOSE: The aim of this study is to evaluate the safety and efficacy of the combination of capecitabine and oxaliplatin (XELOX) as first-line treatment in Chinese patients with metastatic colorectal carcinoma (mCRC). Furthermore, we aimed to explore whether a maintenance therapy with oral capecitabine in patients who were non-progression to the XELOX regimen was able to improve the duration of disease control (DDC). PATIENTS AND METHODS: One hundred twenty-four patients with mCRC received a 3-weekly regimen of oxaliplatin plus capecitabine (XELOX) as first-line treatment. Patients without progressive disease after six cycles ofXELOX could stop treatment or continue to receive oral capecitabine until disease progression or unacceptable toxicity. RESULTS: A total of 637 cycles (median 6 cycles) of XELOX were given to 124 patients (males 58.1%, median age 52 years). The response rate was 49.1% (complete response in 11 patients and partial response in 50 patients). The median overall survival and progression-free survival were 20.0 and 8.0 months, respectively. Main drug-related grade 3-4 toxicities included neutrapenia (5.6%), nausea/vomiting (4%), thrombocytopenia (2.4%), diarrhea (2.4%) and hand-foot syndrome (2.4%). Among 62 patients achievingobjective response or stable disease after at least 6 cycles of XELOX, there were 22 patients received oral capecitabine as maintenance therapy. The median DDC was significantly longer for maintenance therapy group than those of no maintenance group (14 vs. 9 months; P = 0.041). CONCLUSIONS:XELOX is a highly effective first-line treatment for Chinese mCRC patients. The response rate, TTP, and overall survival of patients treated with this regimen are similar to those treated with FU/leucovorin/oxaliplatin. Furthermore, our preliminary data show maintenance therapy with capecitabine for those patients without progressive disease after at least six cycles of XELOX can significantly improve DDC; and further prospective randomized control trial is warranted.
RCT Entities:
PURPOSE: The aim of this study is to evaluate the safety and efficacy of the combination of capecitabine and oxaliplatin (XELOX) as first-line treatment in Chinese patients with metastatic colorectal carcinoma (mCRC). Furthermore, we aimed to explore whether a maintenance therapy with oral capecitabine in patients who were non-progression to the XELOX regimen was able to improve the duration of disease control (DDC). PATIENTS AND METHODS: One hundred twenty-four patients with mCRC received a 3-weekly regimen of oxaliplatin plus capecitabine (XELOX) as first-line treatment. Patients without progressive disease after six cycles of XELOX could stop treatment or continue to receive oral capecitabine until disease progression or unacceptable toxicity. RESULTS: A total of 637 cycles (median 6 cycles) of XELOX were given to 124 patients (males 58.1%, median age 52 years). The response rate was 49.1% (complete response in 11 patients and partial response in 50 patients). The median overall survival and progression-free survival were 20.0 and 8.0 months, respectively. Main drug-related grade 3-4 toxicities included neutrapenia (5.6%), nausea/vomiting (4%), thrombocytopenia (2.4%), diarrhea (2.4%) and hand-foot syndrome (2.4%). Among 62 patients achieving objective response or stable disease after at least 6 cycles of XELOX, there were 22 patients received oral capecitabine as maintenance therapy. The median DDC was significantly longer for maintenance therapy group than those of no maintenance group (14 vs. 9 months; P = 0.041). CONCLUSIONS:XELOX is a highly effective first-line treatment for Chinese mCRC patients. The response rate, TTP, and overall survival of patients treated with this regimen are similar to those treated with FU/leucovorin/oxaliplatin. Furthermore, our preliminary data show maintenance therapy with capecitabine for those patients without progressive disease after at least six cycles of XELOX can significantly improve DDC; and further prospective randomized control trial is warranted.
Authors: M Mackean; A Planting; C Twelves; J Schellens; D Allman; B Osterwalder; B Reigner; T Griffin; S Kaye; J Verweij Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: Thomas Brodowicz; Maciej Krzakowski; Matjaz Zwitter; Valentina Tzekova; Rodryg Ramlau; Nicolae Ghilezan; Tudor Ciuleanu; Branka Cucevic; Kalman Gyurkovits; Ernst Ulsperger; Jacek Jassem; Mislav Grgic; Pinar Saip; Maria Szilasi; Christoph Wiltschke; Maria Wagnerova; Natalya Oskina; Victoria Soldatenkova; Christoph Zielinski; Miklos Wenczl Journal: Lung Cancer Date: 2006-03-29 Impact factor: 5.705
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: S Novello; P Bruzzi; C Barone; R Buosi; A Masotti; G Michetti; M Fioretti; S Barbera; M Spatafora; L Garetto; P Mazzanti; V Dongiovanni; G Selvaggi; L Crinò; G V Scagliotti Journal: Ann Oncol Date: 2007-03-09 Impact factor: 32.976
Authors: M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka Journal: Eur J Cancer Date: 1998-07 Impact factor: 9.162
Authors: W Scheithauer; J McKendrick; S Begbie; M Borner; W I Burns; H A Burris; J Cassidy; D Jodrell; P Koralewski; E L Levine; N Marschner; J Maroun; P Garcia-Alfonso; J Tujakowski; G Van Hazel; A Wong; J Zaluski; C Twelves Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: R Scalamogna; S Brugnatelli; C Tinelli; P Sagrada; E Gattoni; M C Tronconi; A Riccardi; G Luchena; G R Corazza Journal: Oncology Date: 2008-01-11 Impact factor: 2.935
Authors: Mehmet Ali Nahit Sendur; Nuriye Ozdemir; Tahsin Özatlı; Ozan Yazıcı; Sercan Aksoy; Ahmet Siyar Ekinci; Doğan Yazılıtaş; Yusuf Günaydın; Berna Oksuzoglu; Mustafa Benekli; Nurullah Zengin Journal: Med Oncol Date: 2014-08-07 Impact factor: 3.064